Silver Book Fact

In a study of different treatments for Parkinson’s disease, results showed that the disease can be managed for up to 5 years with a reduces risk of dyskinesia.

Rascol O, Brooks D, Korczyn A, De Deyn P, et al. A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson’s Disease Who Were Treated with Ropinirole or Levodopa. N Engl J Med. 2000; 342(20): 1484-91. http://content.nejm.org/cgi/content/abstract/342/20/1484

Reference

Title
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson’s Disease Who Were Treated with Ropinirole or Levodopa
Publication
N Engl J Med
Publication Date
2000
Authors
Rascol O, Brooks D, Korczyn A, De Deyn P, et al.
Volume & Issue
Volume 342, Issue 20
Pages
1484-91
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of…  
  • A clinical trial in Europe found that treating Alzheimer’s patients with an Alzheimer’s drug reduced annual treatment costs by $1,000 per patient.  
  • A $1 billion-investment in Alzheimer’s research that led to research breakthroughs by 2010 could have a 10-to-1 return by 2015, and a 90-to-1 return by 2050.  
  • Use of existing or new drugs/compounds for Alzheimer’s prevention could result in a delay of onset of between 2 and 5 years.  
  • Early Gene Therapy Studies Show Promise for Parkinson’s Disease